| Name | Imanixil |
| Description | Imanixil (HOE-402 free base) is an LDL receptor (LDLR) inducer, a hypolipidemic and hypocholesterolemic compound with antiatherogenic activity that inhibits the production of very low-density lipoproteins (VLDLs).Imanixil acts by stimulating the LDL receptor pathway. |
| In vivo | Treatment with 0.05% (w/w) Imanixil (HOE-402(free base)) resulted in a maximal reduction of serum cholesterol levels in wild-type LDLR+/0 and LDLR0/0 mice by 53%, 56%, and 73%, respectively (P<0.05), and a reduction of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL) cholesterol levels, while high-density lipoprotein (HDL) cholesterol levels increased. (LDL) cholesterol levels, and elevated high-density lipoprotein (HDL) cholesterol levels, Imanixil (HOE-402 (free base)) inhibits the production of VLDL, thereby attenuating the development of atherosclerosis. [2] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (202.87 mM), Sonication is recommended.
|
| Keywords | VLDL | Imanixil | HOE-402(free base) |
| Inhibitors Related | Carvedilol phosphate hemihydrate | 2-Acetamidophenol | 20-HC-Me-Pyrrolidine | Probucol disuccinate | Taurine | Propane-1,2,3-triyl tripalmitate | LDL-IN-3 | PCSK9-IN-10 | Moxonidine | Nicanartine | 1,2-Cyclohexanedione | Atorvastatin Sodium |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Cardiovascular Disease Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |